🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Ipsen clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK and China registers with Ipsen as lead sponsor. Synced 26 Sep 2026
23Current trials
15Recruiting now
3Drugs in these trials
3Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Ipsen is the lead sponsor of 23 current clinical trials in our USA, UK and China registers. 15 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Corabotase, Elafibranor and Botulinum toxin type A. The most-studied condition is Moderate to Severe Glabellar Lines.

Company profile on this site (news, sites, medicines, approvals): Ipsen (FR) →

ClinicalTrials.gov trials by status

  • Recruiting1565%
  • Active, closed835%

Trials by phase

  • Phase 3835%
  • Observational730%
  • Phase 1/2522%
  • Phase 2313%
01

Clinical trials sponsored by Ipsen

23 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
NCT06258902 · Pregnancy Related
Observational Recruiting 2023-09 USA
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
NCT04752774 · Spasticity
Phase 1/2 Recruiting 2021-04 USA
A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
NCT06089616 · Fibrodysplasia Ossificans Progressiva
Observational Recruiting 2024-12 USA
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842 · Primary Biliary Cholangitis (PBC)
Phase 3 Recruiting 2023-08 USA
A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults
NCT06937931 · ClinicalTrials.gov ↗ · Cervical Dystonia
Phase 2 Recruiting 2025-06 UK, USA
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
NCT06447168 · ClinicalTrials.gov ↗ · Primary Biliary Cholangitis
Observational Recruiting 2024-10 UK, USA
A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China
NCT07588880 · ClinicalTrials.gov ↗ · Progressive Familial Intrahepatic Cholestasis
Observational Recruiting 2026-04 China
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07435428 · ClinicalTrials.gov ↗ · Moderate to Severe Glabellar Lines
Phase 3 Recruiting 2026-02 USA
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
NCT07387549 · ClinicalTrials.gov ↗ · Primary Sclerosing Cholangitis
Phase 3 Recruiting 2026-05 USA
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
NCT06850038 · ClinicalTrials.gov ↗ · Alagille Syndrome
Observational Recruiting 2025-04 USA
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
NCT07213817 · ClinicalTrials.gov ↗ · Locally Advanced Solid Tumor, Metastatic Solid Tumor
Phase 1/2 Recruiting 2025-12 USA
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
NCT06833008 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1/2 Recruiting 2025-03 USA
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
NCT07213830 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Metastatic Solid Tumor
Phase 1/2 Recruiting 2026-02 USA
Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy
NCT07556913 · ClinicalTrials.gov ↗ · Pregnancy Related
Observational Recruiting 2026-07 USA
A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07779252 · ClinicalTrials.gov ↗ · Moderate to Severe Glabellar Lines
Phase 3 Recruiting 2026-08 China
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
NCT06047444 · Chronic Migraine
Phase 3 Active, closed 2023-10 UK, USA
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
NCT06055725 · Spasticity as Sequela of Stroke
Observational Active, closed 2023-11 UK, USA
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
NCT04526665 · Primary Biliary Cirrhosis
Phase 3 Active, closed 2020-09 UK, USA
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
NCT05627362 · ClinicalTrials.gov ↗ · Primary Sclerosing Cholangitis
Phase 2 Active, closed 2022-12 UK, USA
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060 · ClinicalTrials.gov ↗ · Episodic Migraine, Chronic Migraine
Phase 2 Active, closed 2024-10 UK, USA
A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07427797 · ClinicalTrials.gov ↗ · Moderate to Severe Glabellar Lines
Phase 3 Active, closed 2026-02 USA
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
NCT06047457 · ClinicalTrials.gov ↗ · Episodic Migraine
Phase 3 Active, closed 2023-09 USA
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
NCT06305247 · ClinicalTrials.gov ↗ · Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma
Phase 1/2 Active, closed 2024-04 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Ipsen trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Ipsen trials

21 conditions
Moderate to Severe Glabellar Lines3Chronic Migraine2Primary Sclerosing Cholangitis2Episodic Migraine2Pregnancy Related2Metastatic Solid Tumor2Advanced Solid Tumor2Spasticity as Sequela of Stroke1Primary Biliary Cirrhosis1Cervical Dystonia1Primary Biliary Cholangitis1Spasticity1Fibrodysplasia Ossificans Progressiva1Primary Biliary Cholangitis (PBC)1Alagille Syndrome1Melanoma1Head and Neck Squamous Cell Carcinoma1Pancreatic Ductal Adenocarcinoma1Colorectal Cancer1Locally Advanced Solid Tumor1Progressive Familial Intrahepatic Cholestasis1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA2113
Clinical trials in UK72
Clinical trials in China22

A trial with sites in more than one country appears in each of those registers.

05

Questions about Ipsen trials

How many clinical trials does Ipsen sponsor?

Ipsen is the lead sponsor of 23 current trials on ClinicalTrials.gov in our USA, UK and China registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Ipsen trials recruiting?

Yes. 15 of its 23 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Ipsen testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are Corabotase (6), Elafibranor (4) and Botulinum toxin type A (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.